Liu, Z., Le, K., Zhou, X., Alexander, J. L., Lin, S., Bewshea, C., Chanchlani, N., Nice, R., McDonald, T. J., Lamb, C. A., Sebastian, S., Kok, K., Lees, C. W., Hart, A. L., Pollok, R. C., Boyton, R. J., Altmann, D. M., Pollock, K. M., Goodhand, J. R., Kennedy, N. A., …Powell, N. (2023). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. The Lancet Gastroenterology & Hepatology, 8(2), 145-156. https://doi.org/10.1016/S2468-1253%2822%2900389-2